Apoptosis in Parkinson's disease: Signals for neuronal degradation

Annals of Neurology

Volumn 53, Issue SUPPL. 3, 2003, Pages

  Tatton, William G ^a   Chalmers Redman, Ruth ^a   Brown, David ^a   Tatton, Nadine ^a   Schapira, ^b   Hunot, ^b   Olanow, ^b   Isacson, ^b   Stocchi, ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Mount Sinai Medical Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; CELL NUCLEUS DNA; CYTOCHROME C; FAS ANTIGEN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MOLECULAR MARKER; PROTEIN BAX; PROTEIN P53;

APOPTOSIS; CELL MEMBRANE PERMEABILITY; HUMAN; IMMUNOCYTOCHEMISTRY; MITOCHONDRIAL MEMBRANE; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

ANTIGENS, CD95; APOPTOSIS; ARABIDOPSIS PROTEINS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CYTOCHROME C GROUP; FATTY ACID DESATURASES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MITOCHONDRIA; NERVE DEGENERATION; PARKINSON DISEASE; PHOSPHORIC MONOESTER HYDROLASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

EID: 0037378897     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10489     Document Type: Review

References (107)

1. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann Neurol 1998;44(suppl 1):S72-S84.
2. Jenner P. Parkinson's disease, pesticides and mitochondrial dysfunction. Trends Neutosci 2001;24:245-246.
3. Sapolsky RM. Cellular defenses against excitotoxic insults. J Neurochem 2001;76:1601-1611.
4. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999;22:123-144.
5. Dawson VL, Dawson TM. Free radicals and neuronal cell death. Cell Death Differ 1996;3:71-78.
6. Gobbel GT, Chan PH. Neuronal death is an active, caspase-dependent process after moderate but not severe DNA damage. J Neurochem 2001;76:520-531.
7. Liu W, Liu R, Chun JT, et al. Kainate excitotoxicity in organotypic hippocampal slice cultures: evidence for multiple apoptotic pathways. Brain Res 2001;916:239-248.
8. Adams JD Jr, Chang ML, Klaidman L. Parkinson's disease -redox mechanisms. Curr Med Chem 2001;8:809-814.
9. Hirsch EC, Hunot S, Faucheux B, et al. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov Disord 1999;14:383-385.
10. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257.
11. Kanazawa I. How do neurons die in neurodegenerative diseases? Trends Mol Med 2001;7:339-344.
12. Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001;2:589-598.
13. Nicotera P. Apoptosis and age-related disorders: role of caspase-dependent and caspase-independent pathways. Toxicol Lett 2002;127:189-195.
14. Wadia JS, Chalmers-Redman RME, Ju WJH, et al. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J Neurosci 1998;18:932-947.
15. Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997;77:1037-1048.
16. Tatton NA, Hagl C, Nandor S, et al. Apoptotic cell death in the hippocampus due to prolonged hypothetmic circulatory arrest: comparison of cyclosporine A and cycloheximide on neuron survival. Eur J Cardiothorac Surg 2001;19:746-755.
17. Tatton NA, Tezel G, Insolia SA, et al. In situ detection of apoptosis in normal pressure glaucoma: a preliminary examination. Surv Ophthalmol 2001;45(suppl 1):S268-S272.
18. Tatton NA, Rideout HJ. Confocal microscopy as a tool to examine DNA fragmentation, chromatin condensation and other apoptotic changes in Parkinson's disease. Parkinsonism Relat Disord 1999;5:179-186.
19. Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 2000;166:29-43.
20. Tatton NA, Maclean-Fraser A, Tatton WG, et al. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol 1998;44(suppl 1):S142-S148.
21. Tatton WG, Chalmers-Redman RME, Ju WJH, et al. Propargylamines induce anti-apoptotic new protein synthesis in serum and NGF withdrawn NGF-differentiated PC12 cells. J Pharmacol Exp Ther 2002;301:753-764.
22. Kohler C, Orrenius S, Zhivotovsky B. Evaluation of caspase activity in apoptotic cells. J Immunol Methods 2002;265:97-110.
23. Troy CM, Salvesen GS. Caspases on the brain. J Neurosci Res 2002;69:145-150.
24. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 2000; 256:12-18.
25. Hartmann A, Hunot S, Michel PP, et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 2000;97:2875-2880.
26. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441-446.
27. Cande C, Cohen I, Daugas E, et al. Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. Biochimie 2002;84:215-222.
28. Loeffler M, Daugas E, Susin SA, et al. Dominant cell death induction by extramitochondrially targeted apoptosis-inducing factor. FASEB J 2001;15:758-767.
29. Susin SA, Daugas E, Ravagnan L, et al. Two distinct pathways leading to nuclear apoptosis. J Exp Med 2000;192:571-580.
30. Daugas E, Nochy D, Ravagnan L, et al. Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett 2000;476:118-123.
31. van Loo G, Schotte P, van Gurp M, et al. Endonuclease G: a mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation. Cell Death Differ 2001;8:1136-1142.
32. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001;412:95-99.
33. Mogi M, Harada M, Kondo T, et al. The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci Lett 1996;220:195-198.
34. Ferrer I, Blanco R, Cutillas B, Ambrosio S. Fas and Fas-L expression in Huntington's disease and Parkinson's disease. Neuropathol Appl Neurobiol 2000;26:424-433.
35. Saraste A. Morphologic criteria and detection of apoptosis. Herz 1999;24:189-195.
36. Tamura T, Said S, Lu W, Neufeld D. Specificity of TUNEL method depends on duration of fixation. Biotech Histochem 2000;75:197-200.
37. Nishizaki K, Yoshino T, Orita Y, et al. TUNEL staining of inner ear structures may reflect autolysis, not apoptosis. Hear Res 1999;130:131-136.
38. Liu S, Edgerton SM, Moore DH II, Thor AD. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 2001;7:1716-1723.
39. Lafarga M, Andres MA, Calle E, Berciano MT. Reactive gliosis of immature Bergmann glia and microglial cell activation in response to cell death of granule cell precursors induced by methylazoxymethanol treatment in developing rat cerebellum. Anat Embryol (Berl) 1998;198:111-122.
40. Negoescu A, Lorimier P, Labat-Moleur F, et al. In situ apoptotic cell labeling by the TUNEL method: improvement and evaluation on cell preparations. J Histochem Cytochem 1996;44:959-968.
41. Deibel MR Jr, Coleman MS. Biochemical properties of purified human terminal deoxynucleotidyltransferase. J Biol Chem 1980;255:4206-4212.
42. Grosse F, Manns A. Terminal deoxyribonucleotidyl transferase (EC 2.7.7.31). In: Burrell F, ed. Methods in molecular biology. Totowa, NJ: Humana Press, 1993:95-105.
43. Agid Y. Aging, disease and nerve cell death. Bull Acad Natl Med 1995;179:1193-1203.
44. Mochizuki H, Goto K, Mori H, Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 1996;137:120-123.
45. Anglade P, Vyas S, Javoy-Agid F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 1997;12:25-31.
46. Kosel S, Egensperger R, von Eitzen U, et al. On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol 1997;93:105-108.
47. Kingsbury AE, Mardsen CD, Foster OJ. DNA fragmentation in human substantia nigra: apoptosis or perimortem effect? Mov Disord 1998;13:877-884.
48. Banati RB, Daniel SE, Blunt SB. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 1998;13:221-227.
49. Whiteside G, Cougnon N, Hunt SP, Munglani R. An improved method for detection of apoptosis in tissue sections and cell culture, using the TUNEL technique combined with Hoechst stain. Brain Res Brain Res Protoc 1998;2:160-164.
50. Hartmann A, Michel PP, Troadec JD, et al. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease? J Neurochem 2001;76:1785-1793.
51. Parone PA, James D, Martinou JC. Mitochondria: regulating the inevitable. Biochimie 2002;84:105-111.
52. Martinou JC, Green DR. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2001;2:63-67.
53. Vieira HL, Haouzi D, El Hamel C, et al. Permeabilization of the mitochondrial inner membrane during apoptosis: impact of the adenine nucleotide translocator. Cell Death Differ 2000;7:1146-1154.
54. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001;292:727-730.
55. Reed JC, Kroemer G. Mechanisms of mitochondrial membrane permeabilization. Cell Death Differ 2000;7:1145.
56. Basanez G, Nechushtan A, Drozhinin O, et al. Bax, but not Bcl-x(L), decreases the lifetime of planar phospholipid bilayer membranes at subnanomolar concentrations. Proc Natl Acad Sci USA 1999;96:5492-5497.
57. Roucou X, Rostovtseva T, Montessuit S, et al. Bid induces cytochrome c-impermeable Bax channels in liposomes. Biochem J 2002;363:547-552.
58. Korsmeyer SJ, Wei MC, Saito M, et al. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000;7:1166-1173.
59. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 2002;16:33-45.
60. Eskes R, Desagher S, Antonsson B, Martinou JC. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 2000;20:929-935.
61. Zamzami N, El Hamel C, Maisse C, et al. Bid acts on the permeability transition pore complex to induce apoptosis. Oncogene 2000;19:6342-6350.
62. Ruffolo SC, Breckenridge DG, Nguyen M, et al. BID-dependent and BID-independent pathways for BAX insertion into mitochondria. Cell Death Differ 2000;7:1101-1108.
63. Halestrap AP, McStay GP, Clarke SJ. The permeability transition pore complex: another view. Biochimie 2002;84:153-166.
64. Narita M, Shimizu S, Ito T, et al. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci USA 1998;95:14681-14686.
65. Brenner C, Cadiou H, Vieira HL, et al. Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene 2000;19:329-336.
66. Shimizu S, Ide T, Yanagida T, Tsujimoto Y. Electrophysiological study of a novel large pore formed by Bax and the voltage-dependent anion channel that is permeable to cytochrome c. J Biol Chem 2000;275:12321-12325.
67. Shimizu S, Matsuoka Y, Shinohara Y, et al. Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells. J Cell Biol 2001;152:237-250.
68. Scorrano L, Ashiya M, Buttle K, et al. A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. Dev Cell 2002;2:55-67.
69. Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001;29:684-688.
70. Chen RW, Saunders PA, Wei H, et al. Involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and p53 in neuronal apoptosis: evidence that GAPDH is upregulated by p53. J Neurosci 1999;19:9654-9662.
71. Xiang H, Kinoshita Y, Knudson CM, et al. Bax involvement in p53-mediated neuronal cell death. J Neurosci 1998;18:1363-1373.
72. Chang NS. A potential role of p53 and WOX1 in mitochondrial apoptosis. Int J Mol Med 2002;9:19-24.
73. Lopes UG, Erhardt P, Yao R, Cooper GM. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997;272:12893-12896.
74. Chang YC, Lee YS, Tejima T, et al. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ 1998;9:79-84.
75. Chen F, Chang D, Goh M, et al. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Cell Growth Differ 2000;11:239-246.
76. Miller FD, Pozniak CD, Walsh GS. Neuronal life and death: an essential role for the p53 family. Cell Death Differ 2000;7:880-888.
77. Schapira AH, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990;55:2142-2145.
78. McNaught KS, Olanow CW, Halliwell B, et al. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2001;2:589-594.
79. Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm 2000;60(suppl):277-290.
80. Sirover MA. New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta 1999;1432:159-184.
81. Berry MD, Boulton AA. Glyceraldehyde-3-phosphate dehydrogenase and apoptosis. J Neurosci Res 2000;60:150-154.
82. Dastoor Z, Dreyer JL. Potential role of nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase in apoptosis and oxidative stress. J Cell Sci 2001;114:1643-1653.
83. Ishitani R, Kimura M, Sunaga K, et al. An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J Pharmacol Exp Ther 1996;278:447-454.
84. Ishitani R, Chuang DM. Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured cerebellar neurons. Proc Natl Acad Sci USA 1996;93:9937-9941.
85. Sawa A, Khan AA, Hester LD, Snyder SH. Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death. Proc Natl Acad Sci USA 1997;94:11669-11674.
86. Fukuhara Y, Takeshima T, Kashiwaya Y, et al. GAPDH knockdown rescues mesencephalic dopaminergic neurons from MPP+-induced apoptosis. Neuroreport 2001;12:2049-2052.
87. Saunders PA, Chalecka Franaszek E, Chuang DM. Subcellular distribution of glyceraldehyde-3-phosphate dehydrogenase in cerebellar granule cells undergoing cytosine arabinoside-induced apoptosis. J Neurochem 1997;69:1820-1828.
88. Tatton WG, Chalmers-Redman RM, Elstner M, et al. Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling. J Neural Transm 2000;60(suppl):77-100.
89. Carlile GW, Chalmers-Redman RM, Tatton NA, et al. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 2000;57:2-12.
90. Ishitani R, Tanaka M, Sunaga K, et al. Nuclear localization of overexpressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons undergoing apoptosis. Mol Pharmacol 1998;53:701-707.
91. Shashidharan P, Chalmers-Redman RM, Carlile GW, et al. Nuclear translocation of GAPDH-GFP fusion protein during apoptosis. Neuroreport 1999;10:1149-1153.
92. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999;59(suppl):1693s-1700s.
93. McGeer PL, Yasojima K, McGeer EG. Inflammation in Parkinson's disease. Adv Neurol 2001;86:83-89.
94. Hirsch EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 1998;44(suppl 1):S115-S120.
95. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002;296:1634-1635.
96. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002;296:1635-1636.
97. Schneider P, Tschopp J. Apoptosis induced by death receptors. Pharm Acta Helv 2000;74:281-286.
98. Hartmann A, Mouatt-Prigent A, Faucheux BA, et al. FADD: a link between TNF family receptors and caspases in Parkinson's disease. Neurology 2002;58:308-310.
99. Hartmann A, Troadec JD, Hunot S, et al. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci 2001;21:2247-2255.
100. Sawa A. Neuronal cell death in Down's syndrome. J Neural Transm 1999;57(suppl):87-97.
101. Seidl R, Bidmon B, Bajo M, et al. Evidence for apoptosis in the fetal Down syndrome brain. J Child Neurol 2001;16:438-442.
102. Mielke K, Herdegen T. JNK and p38 stresskinases - degenerative effectors of signal-transduction-cascades in the nervous system. Prog Neurobiol 2000;61:45-60.
103. Waring P, Mullbacher A. Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol 1999;77:312-317.
104. Reed JC. Apoptosis based therapies. Nat Rev Drug Discov 2002;1:111-121.
105. Kragten E, Lalande I, Zimmermann K, et al. Glyceraldehyde3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem 1998;273:5821-5828.
106. Waldmeier PC, Spooren WP, Hengerer B. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 2000;362:526-537.
107. Waldmeier PC, Boulton AA, Cools AR, et al. Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Transm 2000;60(suppl):197-214.